EVMN · Company research
Evommune, Inc. (EVMN): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight | The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bullish | 1 | 1 |
| Evommune, Inc. $EVMN Stock: Andera Partners Decreases Stake - MarketBeat | Evommune, Inc. $EVMN Stock: Andera Partners Decreases Stake MarketBeat | View source ↗ | MarketBeat | Oct 17, 2026 | neutral | 0 | 0.6 |
| EVMN May 2027 10.000 call (EVMN270521C00010000) Stock Price, News, Quote & History - Yahoo! Finance Canada | EVMN May 2027 10.000 call (EVMN270521C00010000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| At 85% of the closing price, Evommune (EVMN) CEO acquires 1,115 shares through an employee plan. - Stock Titan | At 85% of the closing price, Evommune (EVMN) CEO acquires 1,115 shares through an employee plan. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| EVMN May 2027 12.500 call (EVMN270521C00012500) Stock Historical Prices & Data - Yahoo Finance - Yahoo! Finance Canada | EVMN May 2027 12.500 call (EVMN270521C00012500) Stock Historical Prices & Data - Yahoo Finance Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 14, 2026 | neutral | 0 | 0.6 |
| Evommune (NYSE:EVMN) Stock Bumped Up to "Hold" by UBS Group - MarketBeat | Evommune (NYSE:EVMN) Stock Bumped Up to "Hold" by UBS Group MarketBeat | View source ↗ | MarketBeat | Oct 14, 2026 | neutral | 0 | 0.6 |
| This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits | This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? Stocktwits | View source ↗ | Stocktwits | Oct 14, 2026 | neutral | 0 | 0.6 |
| Evommune Inc (EVMN-N) Stock Price and News - The Globe and Mail | Evommune Inc (EVMN-N) Stock Price and News The Globe and Mail | View source ↗ | The Globe and Mail | Oct 2, 2026 | neutral | 0 | 0.6 |
| $EVMN stock is down 8% today. Here's what we see in our data. - Quiver Quantitative | $EVMN stock is down 8% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 1, 2026 | neutral | 0 | 0.6 |
| After two doses, patients’ eczema responses kept improving for eight weeks. - Stock Titan | After two doses, patients’ eczema responses kept improving for eight weeks. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Evommune, Inc. (NYSE:EVMN) Stock Has Average Target Price of $33.33 According to Analysts - MarketBeat | Evommune, Inc. (NYSE:EVMN) Stock Has Average Target Price of $33.33 According to Analysts MarketBeat | View source ↗ | MarketBeat | Sep 27, 2026 | neutral | 0 | 0.6 |
| Evommune to present Phase 2a atopic dermatitis data | EVMN Stock News - Stock Titan | Evommune to present Phase 2a atopic dermatitis data | EVMN Stock News Stock Titan | View source ↗ | Stock Titan | Sep 23, 2026 | neutral | 0 | 0.6 |
| Evommune: Pipeline Reset After EVO756 Failure, All Eyes On EVO301 (NYSE:EVMN) - Seeking Alpha | Evommune: Pipeline Reset After EVO756 Failure, All Eyes On EVO301 (NYSE:EVMN) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 22, 2026 | neutral | 0 | 0.6 |
| Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline? - Yahoo Finance | Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 16, 2026 | neutral | 0 | 0.6 |
| $EVMN stock is down 15% today. Here's what we see in our data. - Quiver Quantitative | $EVMN stock is down 15% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 9, 2026 | neutral | 0 | 0.6 |
| Why Is EVMN Stock Down 13% After-Hours? - Stocktwits | Why Is EVMN Stock Down 13% After-Hours? Stocktwits | View source ↗ | Stocktwits | Sep 8, 2026 | neutral | 0 | 0.6 |
| Independent Director of Evommune Arthur Kirsch Buys More Stock - Simply Wall Street | Independent Director of Evommune Arthur Kirsch Buys More Stock Simply Wall Street | View source ↗ | Simply Wall Street | Jul 10, 2026 | neutral | 0 | 0.6 |
| Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky - PR Newswire | Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky PR Newswire | View source ↗ | PR Newswire | Jul 7, 2026 | neutral | 0 | 0.6 |
| EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal - Zacks Investment Research | EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal Zacks Investment Research | View source ↗ | Zacks Investment Research | Jun 30, 2026 | neutral | 0 | 0.6 |
| Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN) - PR Newswire | Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN) PR Newswire | View source ↗ | PR Newswire | Jun 30, 2026 | neutral | 0 | 0.6 |
| EVMN Forecast — Price Target — Prediction for 2027 - TradingView | EVMN Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.